Atopic Dermatitis

Combination treatment of dupilumab and topical corticosteroid treatment improved itch, mood and quality of life in adult patients with moderate-to-severe atopic dermatitis, according to a new trial.

Multiple burning, painful skin lesions appear on the legs the morning after a walk in the woods. What’s your diagnosis?

A study presented at EADV in Paris today showed that dupilumab met its primary endpoints in a phase three study of adolescents with moderate-to-severe atopic dermatitis.

In this slideshow, we highlight some of the most innovative and important clinical advances in the treatment of atopic dermatitis.

The biologic dupilumab is projected to be a cost-effective treatment for moderate-to-severe atopic dermatitis, shows a new study.  (©Dzm1try/Shutterstock.com)

Topical vitamin A provides no benefit in treating atopic dermatitis, whereas topical vitamin D may actually exacerbate symptoms, according to an evidence-based review.

A summary of treatments for atopic dermatitis in children. 

Physicians spell out knowns and unknowns associated with treating pediatric atopic dermatitis.

Study shows that blocking IL-13 improves atopic dermatitis ― a promising finding for IL-13 atopic dermatitis drugs in development.

Patients with moderate-severe atopic dermatitis are at high risk of having inadequate disease control, according to a cross-sectional study in JAMA Dermatology.

Study finds the combination of duplilumab and topical corticosteroids works in hard-to-treat atopic dermatitis cases in adult patients.

 FDA approves early, pre-approval trials for pediatric cases

The skin care industry promotes products designed for sensitive skin, yet dermatologists are concerned about the use of skin care products for skin disease.

Skin biopsies from infants with atopic dermatitis feature important differences compared to adults with atopic dermatitis. These differences could change atopic dermatitis treatment for infants and toddlers with the disease, a study shows.

This week during the annual meeting of the American Academy of Dermatology in San Diego, Robert Sidbury, M.D., addressed developments in atopic dermatitis treatments since the publication of treatment guidelines in 2014.

A daily capsule of a cocktail of probiotics may reduce both the severity symptoms in moderate atopic dermatitis and the need for topical corticosteroids to treat symptom flare ups in children.

All children, but healthy controls, had a higher likelihood of behavioral issues. ADHD symptoms of attention, hyperactivity and impulse control, were higher in AD children. Quality of life lower in affected children.

In this article, Drs. Lawrence Eichenfield and Jessica Sprague review some of the most significant findings and developments in pediatric dermatology from the last year beginning with the availability of biologic agents for pediatric psoriasis and atopic dermatitis.

The first patient has been dosed in the phase two study of PR022 (hypochlorous acid, Realm Therapeutics), a topical gel treatment for patients with atopic dermatitis.

A small study finds that the combination of methotrexate and azathioprine is safe and effective as maintenance treatment for patients with moderate-to-severe atopic dermatitis for up to five years.

Moisturizers were described as the “cornerstone of therapy” in atopic dermatitis in the 2014 AAD guidelines for topical therapies in atopic dermatitis, but the products differ greatly by ingredients which can improve the condition or make it worse.

Adult AD may be influenced by childhood eczema, though most adults have no memory of childhood eczema.

Drug development for established atopic dermatitis focuses on both managing flares and long-term disease control.

Most moisturizes contain ingredients that are not advertised and could potentially harm some patients, study shows.

Adding caffeine to topical skin treatments would be a simple way to reduce inflammation in patients with atopic dermatitis and psoriasis, suggests a review presented at the Psoriasis: From Gene to Clinic International Congress, which took place in London this week.

In this slideshow, we summarize the phenotypes associated with childhood atopic dermatitis as addressed recently in JAMA Pediatrics.

The International Eczema Council (IEC) is recommending that the routine use of systemic corticosteroids for atopic dermatitis be discouraged and instead, it should be reserved for special circumstances.

A round-up of the latest products hitting the dermatology market including treatment for eczema and wounds, plus care for rejuvenating procedures.

Treatment for atopic dermatitis isn’t always straightforward. In this article, a physician outlines treatment approaches.